brl2 Antibody

Basic Research Questions

• What is BRD2 and why is it significant in SARS-CoV-2 research?

BRD2 (Bromodomain-containing protein 2) is a transcriptional regulator and part of the Bromodomain and Extra-terminal domain (BET) family of proteins that includes Brd3, Brd4, and BrdT . These proteins function as master transcriptional regulators, serving as bridges between chromatin marks (primarily acetyl-lysines) and the transcriptional machinery . BRD2's significance in SARS-CoV-2 research stems from its critical role in regulating ACE2 expression.

Research has identified BRD2 as a major node for host-SARS-CoV-2 interaction . Inhibition of BRD2 has been shown to downregulate ACE2 expression in multiple cell types, including Calu-3 cells, iPSC-derived cardiomyocytes, primary human lung epithelial cells, and reconstructed human nasal epithelia . Since ACE2 serves as the primary receptor for SARS-CoV-2 entry into host cells, targeting BRD2 represents a potential therapeutic strategy for inhibiting viral infection by reducing the availability of entry receptors.

• How do antibodies function in targeting conserved regions of SARS-CoV-2?

Antibodies targeting conserved regions of viral proteins offer significant advantages for broad-spectrum neutralization. Several monoclonal antibodies (mAbs) have been identified that recognize the S2 region of the SARS-CoV-2 spike protein, which remains remarkably consistent across different variants .

The mechanism involves antibody recognition of highly conserved epitopes, particularly within the heptad repeat 2 (HR2) domain. For example, mAbs Mab5 and Mab3-2 bind specifically to the CB-119 epitope located in the HR2 region with high affinity (KD values of 4.88 pM and 32.85 pM, respectively) . These antibodies demonstrated neutralizing ability against SARS-CoV-2, with Mab5 showing an IC50 value of 12.3 μg/mL, indicating superior neutralizing activity compared to Mab3-2 (IC50 of 87.4 μg/mL) . The effectiveness of these antibodies stems from their ability to recognize domains that remain unchanged even as the virus evolves in other regions.

• What are the structural features that determine antibody specificity and function?

Antibody specificity and function are determined by several key structural elements:

The basic immunoglobulin (Ig) structure consists of two identical halves connected by disulfide bonds, with each half comprising a heavy chain (~50 kDa) and a light chain (~25 kDa) . This Y-shaped molecule can be divided into:

• Fab portion: Located at the amino terminal (arms of the Y), containing both heavy and light chains joined by a disulfide bond. Each Fab region contains one antigen-binding site .

• Fc portion: Found at the carboxyl terminal (base of the Y), composed only of heavy chains and containing carbohydrate attachments. This region can bind to receptors on immunomodulatory cells like macrophages .

The antigen-binding specificity resides within the variable regions, which contain three distinct hypervariable regions termed Complementary Determining Regions (CDRs) . These CDRs are surrounded by four relatively conserved Framework Regions (FRs) that constitute the majority of the β-sheets . The Framework Regions establish a scaffolding platform upon which the CDRs build up the antigen-binding sites .

This structural organization allows each antibody to bind two antigen molecules simultaneously, while the Fc region mediates effector functions including complement activation and interaction with immune cells.

• What techniques are used to validate antibody specificity for BRD2?

Validating antibody specificity for BRD2 requires multiple complementary approaches:

Western Blotting: This technique confirms that the antibody recognizes a protein of the expected molecular weight (approximately 110 kDa for BRD2). Comparing results between wild-type cells and BRD2 knockdown cells (using CRISPRi or siRNA) is essential for validation, as demonstrated in studies where CRISPRi knockdown of BRD2 robustly reduced Brd2 protein levels .

Immunoprecipitation followed by Mass Spectrometry: This approach identifies proteins pulled down by the antibody, confirming BRD2 as the primary target and revealing any cross-reactivity with other BET family members like BRD3 or BRD4.

Chromatin Immunoprecipitation (ChIP): Since BRD2 functions as a transcriptional regulator, ChIP assays validate antibody specificity by demonstrating enrichment at known BRD2-binding genomic loci. This provides functional validation beyond simply recognizing the protein.

Rescue Experiments: Transgenic expression of full-length BRD2 in knockdown cells should restore target gene expression (like ACE2), while expression of truncation mutants typically fails to rescue the phenotype, as observed in studies where truncation mutants of BRD2 did not rescue ACE2 expression .

Cross-reactivity Testing: Evaluating potential cross-reactivity with other BET family members (BRD3, BRD4, BRDT) through parallel knockdown experiments helps ensure specificity within this closely related protein family.

Advanced Research Applications

• How can researchers utilize BRD2 antibodies to investigate ACE2 regulation during SARS-CoV-2 infection?

Investigating BRD2's role in ACE2 regulation during SARS-CoV-2 infection requires sophisticated experimental approaches using BRD2 antibodies:

Chromatin Immunoprecipitation sequencing (ChIP-seq): BRD2 antibodies can be used to immunoprecipitate BRD2-bound chromatin, followed by sequencing to map genome-wide BRD2 binding sites before and after SARS-CoV-2 infection. This approach can determine whether BRD2 directly associates with the ACE2 promoter or enhancer regions and whether this association changes during infection.

Co-immunoprecipitation (Co-IP) with transcriptional complexes: BRD2 antibodies can pull down BRD2-containing complexes to identify binding partners that may co-regulate ACE2 expression. Mass spectrometry analysis of these complexes can reveal how the transcriptional machinery around BRD2 is altered during viral infection.

Proximity ligation assays (PLA): Combining BRD2 antibodies with antibodies against other transcription factors can visualize protein-protein interactions at the ACE2 locus in situ, providing spatial information about regulatory complex assembly.

ChIP-qPCR time course experiments: Using BRD2 antibodies for ChIP followed by qPCR targeting ACE2 regulatory regions at different time points after infection can track the dynamics of BRD2 recruitment and dissociation.

Research has demonstrated that transgenic expression of full-length BRD2 restores ACE2 transcript levels in BRD2 knockdown cells, while truncation mutants fail to rescue expression . This indicates that complete BRD2 functionality is required for proper ACE2 regulation, suggesting complex interactions with other transcriptional components.

• How do bispecific antibodies enhance neutralization potential against SARS-CoV-2 variants?

Bispecific antibodies represent an innovative approach to target multiple epitopes simultaneously, enhancing neutralization breadth against diverse SARS-CoV-2 variants:

Mechanism of action: Bispecific (or "dual") antibodies like the CoV2-biRN series are engineered to attach to two distinct regions of the viral spike protein . The first binding site typically targets a non-mutating region within the spike N-terminal domain (NTD) that remains consistent across variants . While this region alone might not be directly therapeutic, attachment here creates a stable anchor point. The second binding site then targets the receptor-binding domain (RBD), effectively blocking the virus from attaching to ACE2 receptors on human cells .

Laboratory validation: These dual antibodies have demonstrated high neutralization of all known SARS-CoV-2 variants that cause illness in humans . In animal models, they significantly reduced viral load in the lungs of mice exposed to omicron variants .

Design considerations: When designing bispecific antibodies, researchers must consider:

• Epitope accessibility when both binding sites are engaged

• Optimal linker length between binding domains

• Binding kinetics of each arm

• Potential for aggregation or improper folding

The bispecific approach offers particular advantages when dealing with rapidly mutating viruses since it creates a dependency on two simultaneous escape mutations for the virus to evade neutralization, which is statistically much less likely than a single mutation.

• What are the methodological differences between using antibodies versus small molecule inhibitors for studying BRD2 function?

Researchers have multiple tools to study BRD2 function, each with distinct methodological considerations:

BRD2 Antibodies:

• Specificity: Antibodies can distinguish between closely related BET family members when properly validated

• Applications: Suitable for protein detection (Western blot, IHC), localization studies (ICC/IF), protein complex analysis (IP), and chromatin binding analysis (ChIP)

• Limitations: Cannot easily enter living cells (except with specialized delivery methods), making them less suitable for functional studies in intact cells

• Temporal control: Limited ability to initiate rapid inhibition in experimental settings

Small Molecule Inhibitors:

• Cell permeability: Small molecules like JQ1, ABBV-744, and PROTAC compounds readily enter cells, allowing functional studies in living systems

• Rapid action: Effects can be observed within hours (24-72 hours showed dramatic reduction in ACE2 mRNA with BRD2 inhibitors)

• Selectivity challenges: Many inhibitors target the entire BET family rather than BRD2 specifically

• Dosage control: Allow for precise titration of inhibition levels

• Reversibility: Effects can be washed out to restore function

Comparative approach: Using both methods in parallel provides complementary insights. For example, studies have shown that both genetic knockdown of BRD2 and pharmacological inhibition with BET inhibitors led to substantial decreases in ACE2 expression, with almost no ACE2 mRNA detectable after 72 hours of treatment with BRD2-targeting compounds .

The choice between these approaches depends on the specific research question. For validating direct BRD2 binding to a promoter, ChIP with BRD2 antibodies is appropriate. For assessing functional consequences of BRD2 inhibition on viral infection, small molecule inhibitors like ABBV-744 (currently in clinical trials NCT03360006 and NCT04454658) may be more suitable .

• What factors influence the selection of appropriate antibody formats for SARS-CoV-2 research?

Selecting the optimal antibody format for SARS-CoV-2 research depends on the specific experimental goals and conditions:

For SARS-CoV-2 spike protein studies, researchers should consider:

• Epitope location: For targeting conserved regions like the HR2 domain in the S2 subunit, affinity-isolated monoclonal antibodies have demonstrated success, as seen with Mab5 (KD of 4.88 pM) and Mab3-2 (KD of 32.85 pM) .

• Cross-reactivity requirements: When studying multiple coronavirus strains, antibodies targeting highly conserved epitopes like CB-119 in the HR2 region show 100% sequence identity between SARS-CoV-1 and SARS-CoV-2 .

• Binding kinetics: Off-rate constants are particularly important for neutralization studies, with slower off-rates (e.g., 10⁻⁶/s for humanized mAb hMab5.17) indicating stronger antigen-binding ability and better neutralization potential .

• Fragment utilization: F(ab)₂ fragments may be advantageous when studying lung tissues containing macrophages with Fc receptors, which could otherwise cause high background staining .

The research context ultimately determines format selection. For neutralization assays, intact IgG or F(ab)₂ with demonstrated neutralizing capability would be appropriate, while immunohistochemistry in lung tissues might benefit from F(ab)₂ fragments to avoid Fc-mediated binding.

Therapeutic Applications and Future Directions

• How do BRD2 inhibition strategies compare with antibody-based approaches for SARS-CoV-2 treatment?

BRD2 inhibition and antibody-based approaches represent distinct therapeutic strategies with different mechanisms, advantages, and limitations:

BRD2 Inhibition Approach:

• Mechanism: Acts indirectly by reducing host ACE2 receptor expression, thereby limiting SARS-CoV-2 cellular entry

• Breadth of protection: Potentially effective against all variants that use ACE2 for entry, since it targets the host rather than the virus

• Development status: Several BRD2 inhibitors are already in clinical trials for cancer indications, potentially accelerating repurposing (ABBV-744 is in clinical trials NCT03360006 and NCT04454658)

• Time to effect: Requires 24-72 hours to significantly reduce ACE2 expression, with almost complete suppression after 72 hours

• Potential concerns: May affect normal ACE2 physiological functions; may alter expression of other genes regulated by BRD2

Antibody-Based Approaches:

• Mechanism: Direct neutralization of virus particles by binding to spike protein, preventing cellular attachment and entry

• Specificity: Highly targeted to viral components with minimal direct effect on host cellular processes

• Variant susceptibility: Traditional approaches targeting variable regions like RBD may lose efficacy against new variants

• Novel solutions: Bispecific antibodies like CoV2-biRN targeting both conserved regions (NTD) and the RBD show high neutralization against all known variants

• Immediate action: Provides immediate neutralizing activity upon administration

Complementary potential: These approaches could theoretically be combined for synergistic effect:

• BRD2 inhibitors reducing new ACE2 expression over several days

• Neutralizing antibodies providing immediate protection during this window

• Bispecific antibodies offering broad coverage against emerging variants

In animal models, BRD2 inhibition with ABBV-744 inhibited SARS-CoV-2 replication in Syrian hamsters , while bispecific antibodies significantly reduced viral load in the lungs of mice exposed to omicron variants . Both approaches show promise, but with different onset timing and mechanisms of action.

• What are the considerations for humanizing and optimizing antibodies targeting conserved coronavirus regions?

Developing humanized antibodies targeting conserved coronavirus regions involves several critical considerations:

Epitope selection and conservation analysis:

• Sequence alignment across coronavirus strains is essential to identify truly conserved regions. For example, the HR2 domain in the S2 subunit shows 100% identity between SARS-CoV-1 and SARS-CoV-2, making it an ideal target .

• The neutralizing epitope CB-119 recognized by mAbs Mab5 and Mab3-2 demonstrates complete conservation between these viruses .

• Cross-reactivity testing should systematically evaluate binding against multiple coronavirus S proteins through immunoblot analysis and ELISA with purified proteins .

Humanization process optimization:

• Framework selection is critical. The humanized version of Mab5 (hMab5.17) maintained favorable affinity (KD of 13 pM) and neutralizing ability (IC50 of 12.2 μg/mL) comparable to its parental antibody .

• Binding kinetics must be preserved or enhanced during humanization. The humanized hMab5.17 demonstrated an exceptionally slow off-rate constant (10⁻⁶/s), indicating strong antigen-binding properties .

• Complementary Determining Regions (CDRs) must be carefully preserved during humanization, as these hypervariable regions directly contact the antigen, while Framework Regions (FRs) provide the scaffold for CDR positioning .

Functional validation requirements:

• Binding affinity determination through biolayer interferometry (BLI) provides quantitative KD values

• Neutralization assays with live virus to determine IC50 values

• Epitope mapping to confirm preservation of binding to the intended conserved region

• Thermal stability assessment to ensure proper folding and stability of the humanized antibody

The humanization process requires balancing the removal of immunogenic mouse sequences while preserving the critical antigen-binding properties. Successful examples like hMab5.17 demonstrate that this can be achieved while maintaining or even enhancing key parameters like off-rate constants that contribute to neutralization efficacy.